Megakaryocyte differentiation pathway

The megakaryocyte differentiation pathway comprises a network of signaling, gene expression, and epigenetic events governing the production of megakaryocytes—the precursor cells for platelets—from HSCs within the bone marrow. This process involves sequential and/or direct differentiation routes, regulated primarily by thrombopoietin and various cytokines, as well as transcription factors including GATA1, FLI-1, RUNX1, and NFE2. Epigenetic modifications (notably DNA methylation) are crucial for lineage commitment and terminal differentiation. Abnormal regulation of this pathway is implicated in diseases such as myeloproliferative neoplasms, leukemia, and thrombocytopenia. Crucially, the pathway does not correspond to a single identifiable molecule or drug target, but rather a constellation of molecular events and cellular transitions. If a specific molecule or receptor involved in the megakaryocyte differentiation pathway is needed (such as thrombopoietin receptor or GATA1), please specify, as those would meet criteria for a structured target entry.

Other names

Megakaryopoiesis pathwayMegakaryocyte lineage differentiationMegakaryocyte development pathway

Cytokine signaling modulation (e.g., thrombopoietin mimetics); Epigenetic modification (e.g., DNA methylation agents); Transcription factor activation/inhibition